Moody Lynn & Lieberson’s Teva Pharmaceuticals TEVA Stock Holding History

Moody Lynn & Lieberson’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-62,605	Closed	-$4.11M	–	189
2015 Q4	$4.11M	Sell	62,605 -33,005	-35%	-$2.04M	0.65%	59
2015 Q3	$5.4M	Buy	95,610 +72	+0.1%	+$4.67K	1.04%	38
2015 Q2	$5.65M	Sell	95,538 -2,216	-2%	-$137K	0.9%	44
2015 Q1	$6.09M	Sell	97,754 -67,046	-41%	-$3.9M	0.97%	39
2014 Q4	$9.48M	Buy	164,800 +37,854	+30%	+$2.11M	1.35%	27
2014 Q3	$6.82M	Buy	+126,946	New	+$6.73M	1.02%	32

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Moody Lynn & Lieberson's TEVA Position: Q1 2016 in Review

Moody Lynn & Lieberson sold out of Teva Pharmaceuticals (TEVA) in Q1 2016, closing a stake of 62,605 shares — an estimated $4.11M sold.

Moody Lynn & Lieberson first reported a position in TEVA in Q3 2014 and held it in 6 quarters. The position peaked at $9.48M in Q4 2014. 836 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

Moody Lynn & Lieberson reported no remaining Teva Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Moody Lynn & Lieberson sold 62,605 Teva Pharmaceuticals shares in Q1 2016, an estimated $4.11M.
Moody Lynn & Lieberson first reported a position in Teva Pharmaceuticals in Q3 2014 and held it in 6 quarters.
Moody Lynn & Lieberson's Teva Pharmaceuticals position peaked at $9.48M in Q4 2014.
836 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on Moody Lynn & Lieberson's 13F filing for Q1 2016, filed 2 May 2016.